Overview
Injective vs VBILL is one of the most watched crypto matchups. Beyond headline prices, this comparison blends market structure, technical readings and probabilistic context without promising outcomes.
Quick winners
Full comparison
| Metric | INJ | VBILL |
|---|---|---|
| Price | $5.00 | $1,867.53 |
| Market Cap | $490.41M | $193.10M |
| FDV | — | — |
| Volume 24h | $2.50M | $0.000000 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 164.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | VBILL |
|---|---|---|
| 1H | — | — |
| 24H | +1.77% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | VBILL |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
When RSI and trend disagree across Injective and VBILL, expect choppy relative performance until one side reclaims a clear structure.
Fundamentals
| Metric | INJ | VBILL |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
VBILL
Pros and cons
Pros of Injective
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Higher ranking for Injective can translate into tighter spreads on major venues.
- INJ often anchors narratives that attract sustained media and analyst coverage.
Cons of Injective
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
Pros of VBILL
- If technical momentum aligns, VBILL may outperform on medium-term windows.
- VBILL can offer higher relative beta when market attention rotates toward its niche.
- Diversifying versus Injective with VBILL can change portfolio factor exposure.
Cons of VBILL
- Relative underperformance versus Injective can persist through entire market regimes.
- Weaker market-cap standing may leave VBILL more exposed to liquidity droughts.
- Higher volatility on VBILL cuts both ways and demands stricter risk limits.
Which looks stronger right now?
The “stronger” label here is descriptive, not predictive. Injective and VBILL can alternate leadership as macro liquidity and narrative rotate.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #99; VBILL shows $193.10M and #164. Where liquidity and flow matter, watch Injective. Where durability matters, watch Injective. AI composite scores (46.90/57.90) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or VBILL?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or VBILL?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and VBILL.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.